CompanyWuXi Biologics Inc.
China
WuXi Biologics is a leading global biologics services provider that offers comprehensive, integrated and highly customizable services. The company offers multinational pharmaceutical and biotechnological companies in the world end-to-end solutions empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing. Their services are designed to help their worldwide clients shorten the discovery and development time and lower the cost of biol...
The company has 7 seperate service facilities in China, Germany, Ireland, United States of America.
Private/Public:
public
Phone:+86 510-8183-1200
Fax:852 2861 0285
Email:[email protected]
Website:https://www.wuxibiologics.com/
Address:108 Meiliang Road. W, MaShan Binhu District, Wuxi 214092, China
2008
Since
7
facilities at 4 Countries
9
Top Service Categories
213
Sub-Service Categories
Top Services
Product Groups
For Services/Products
Analytical
Analytical Equipment
Analytical lab services
- Sample Type
- Service Type
- CMC analytical- Protein/Peptide/DNA/Oligo
- Antibody sequencing
- Antigen & antibody purity
- Binding assays
- Biological QC testing (Cell-based assay)
- Biologics safety testing
- Biophysical assays
- Biosimilar comparability testing
- Characterization of antibody-drug conjugates
- Chromatography (SEC, IEC)
- Disulfide bridge analysis
- DNA/RNA sequencing
- Electrophoresis (SDS-PAGE, IF, CE)
- Enzyme testing
- Glycan microarray analysis
- Glycosylation Profile
- Isoelectric point/charge
- Molecular weight determination
- N-Terminal sequencing
- Oligonucleotide analytics
- Oligosaccharide analysis
- PEGylation analysis
- Peptide analysis
- Peptide/protein mapping
- Peptide/protein primary structure
- Protein aggregation/deaggregation
- Protein biophysical characterization
- Protein carbohydrate analysis
- Protein chemical stability
- Protein identification/characterization
- Protein quantitation with isotope labeling
- Protein secondary/tertiary structure
- Protein sialic acid analysis
- Viral clearance testing
- Methods
- Test - Release
- Test-Instrumental
- Tests - Physical
- Tests - Purity Related
- Tests - Stability
- Tests/Analysis - Other
- CMC analytical- Protein/Peptide/DNA/Oligo
Discovery and Preclinical
Specific Services-Discovery
Supply Chain
Supply Chain Management
API/Biologicals Production
API/Biologics development and manufacturing
- API development phases/scales
- API process capabilities
- API process equipment
- API reactions
- Biologics development and manufacturing
- Antibody/protein/viral vectors/vaccine mfg.
- Antibody types
- Cloning/Vectors
- Downstream process development
- Expression systems
- Microbial/Antigen API services
- Protein API services
- Antibody/protein/viral vectors/vaccine mfg.
Reagents/excipients manufactured
Microbiology
Specific Services - microbiology
Bioanalytical
Bioanalytical assays
Formulation
Formulation development related
Formulation types
Manufacturing Equipment
Package and Label
Specific Services - Packaging etc.
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing API Biological,Manufacturing Formulation | Leverkusen | Leverkusen | Germany | Acquired from Bayer in April of 2020, will be ready in Q4 2020, commercial manufacturing | |||||||
| Manufacturing Formulation | Wuxi city - DP1, DP2, DP3, DP4 | Wuxi city | China | ||||||||
| Manufacturing Formulation | Dundalk, Ireland | Dundalk | Ireland | Commercial production, cGMP Ready 2022 | |||||||
| Manufacturing Facilities | Cranbury, New Jersey | Cranbury | United States of America | NJ-New Jersey | 66000 square foot | ||||||
| Manufacturing Facilities | Suzhou City | Suzhou City | China | 10116 square meter | |||||||
| R&D/Innovation Centers | Hangzhou, Zhejiang province | Hangzhou | China | ||||||||
| Global Corporate Headquarters | 108 Meiliang Road. W, MaShan Binhu District, Wuxi 214092 | +86 510-8183-1200 | Wuxi | 852 2861 0285 | China | ||||||
| 288 Fute Zhong RoadWaigaoqiao Free Trade ZoneShanghai 200131 | +86 (400)-820-0985 | Shanghai | China |
- (28.Sep.2021) BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission
- (24.Sep.2021) BioVaxys Entered into an Agreement with Millipore-Sigma
- (14.Sep.2021) BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis of Recombinant SARS-CoV-2 S-Proteins for BVX-0320 and CoviDTH Programs
- (01.Sep.2021) WuXi Biologics Received First Manufacturing License From Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date
- (23.Aug.2021) WuXi Biologics Reports Strong 2021 Interim Results
- (02.Aug.2021) WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
- (02.Aug.2021) CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China's National Medical Products Administration
- (26.Jul.2021) WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for Its German Drug Product Facility
- (01.Jul.2021) WuXi Biologics Awarded as "Most Honorable Company" in Healthcare and "Best ESG Company", "Best CEO" by Institutional Investor
- (27.May.2021) WuXi Biologics Wins 2021 Top Graduate Employers Award in China
- (26.May.2021) WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
- (16.May.2021) Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-In-Human Trial
- (13.May.2021) WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
- (07.May.2021) WuXi Biologics Completed Three Acquisitions to Enhance Its Global Network
- (15.Apr.2021) License Agreement with WuXi Biologics (Hong Kong) Limited
- (13.Apr.2021) WuXi Biologics Receives 2021 Asia-Pacific Bioprocessing Excellence Award From IMAPAC
- (08.Apr.2021) WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA)
- (06.Apr.2021) WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
- (23.Mar.2021) 2020 Results Record High Despite a Challenging Year
- (17.Mar.2021) WuXi Biologics to Acquire CMAB and Form Strategic Partnership With CBC Group
- (16.Mar.2021) WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19
- (16.Mar.2021) WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities From Pfizer China
- (15.Mar.2021) BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins for Its SARS-CoV-2 Vaccine and COVID-T Immunodiagnostic Programs
- (09.Mar.2021) First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore
- (08.Mar.2021) Exelixis Enters Into Exclusive License Agreement With WuXi Biologics to Support Further Expansion of Its Growing Oncology Biologics Pipeline
- (03.Mar.2021) Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
- (24.Feb.2021) WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
- (08.Feb.2021) The World's Largest 36,000L Biomanufacturing Line Using Single-Use Bioreactors Launches GMP Operation at WuXi Biologics
- (08.Feb.2021) WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
- (01.Feb.2021) WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage
- (19.Jan.2021) Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody Platform
- (31.Dec.2020) Duality Biologics Completed Series A Financing
- (28.Dec.2020) WuXi Biologics Receives GMP Certification From Brazil's ANVISA
- (21.Dec.2020) WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany From Bayer
- (16.Dec.2020) Immutep Upscales Efti Manufacturing
- (14.Dec.2020) GMP Inspection Completed by ANVISA at WuXi Biologics DS Facility
- (10.Dec.2020) Arcus Biosciences Expands Strategic Relationship With WuXi Biologics to Develop a Best-In-Class Anti-Cd39 Antibody for the Treatment of Cancer
- (02.Dec.2020) Tubulis Forms Strategic Partnership With WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates Towards Clinical Evaluation
- (20.Nov.2020) WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou
- (19.Nov.2020) IPS Successfully Delivers a Fast-Paced Project Amid COVID-19
- (09.Nov.2020) AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune's Anti-TDP-43 Antibodies Into Clinical Development
- (29.Oct.2020) WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig Alfa
- (27.Oct.2020) Wuxi Biologics Unveils New PD Facility in King of Prussia, Pennsylvania
Analytical Equipment
Bioanalytical/genomics equipment
Chromatography equipment
Electrophoresis
Spectroscopy Equipment E
Manufacturing Equipment
Air/dust water/solvent handling systems
Drying process/equipment
Freeze drying/lyophilization equipment
Packaging process/equipment
Facility Inspection/License Status
Certifications/Accreditations
Country Regulatory/Accreditation
| Process | Capacity Low | Capacity High | Unit |
|---|---|---|---|
| Vial | 15,000 | 200,000 | units/batch |
| Prefilled syringe | 3,150 | 12,000 | units/batch |
| Vial-lyophilized | 6,000 | 47,400 | units/batch |